Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04821544
Other study ID # 20-024
Secondary ID 5U54GM104944-08
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2021
Est. completion date June 30, 2025

Study information

Verified date September 2023
Source University of Idaho
Contact Yimin Chen, PhD
Phone 2088857264
Email yiminc@uidaho.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overarching purpose of this study is to determine if a modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) will reduce stress and increase self-compassion in mothers of preterm infants and beneficially modify the human milk produced, and subsequently improve infant health.


Description:

During every two-week period, newly admitted preterm infants (<36 weeks gestational age) will be recruited at performance site OHSU NICU and block-randomized to either control (standard of care) or intervention (modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) group. The purpose of the nested cohorts is to minimize the postpartum time difference among cohort mothers. Each nested MBSC cohort will undergo the 8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator. Maternal data: The Perceived Stress Scale (PSS) and Self-Compassion Scale-Short Form (SCS-SF) will be given to mothers from both groups pre- and post-intervention, and during the 4th week. Saliva, urine, stool, and human milk samples will be collected at the same time points as above. Additional maternal data include: age, race, height, weight (pre-pregnancy and last weight before delivery), parity, delivery mode, chorioamnionitis, preeclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome, antenatal antibiotics, anti-depressants or other mood-altering/neurochemical medications (current and during pregnancy), diagnosis of depression or other mental illness within the previous 5 years, history of postpartum depression and postpartum psychosis, diabetes, hypertension, heart disease, and any inflammatory or autoimmune diseases. Infant data: Gestational age, birth weight, ventilation requirement, surgical interventions, patent ductus arteriosus, growth, nutrition prescriptions, saliva, urine and stool samples. Data collection: All data (not including biosamples) will be collected using REDCap hosted within the UI system. Sample measurements: Maternal salivary cortisol (marker of stress) and oxytocin (marker of anxiety and "social-closeness") concentrations will be measured using ELISA. Human milk proteins will be identified using mass spectrometry-based proteomics. Following proteomic analyses, targeted proteins will be quantified using ELISA and Western Blot. Both maternal and infant saliva, urine and stool samples will be used for metabolomic and transcriptomic sequencing to identify metabolic and molecular changes, respectively, in both mothers and infants. Infant systemic oxidative stress will be measured through urine F2-isoprostanes concentrations (ELISA), and infant intestinal inflammation will be determined with stool calprotectin concentrations (ELISA).


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Mothers of preterm infants (<36 weeks gestation) at Oregon Health and Sciences University Exclusion Criteria: -

Study Design


Intervention

Behavioral:
Mindfulness-based intervention (with a focus on self-compassion; MBSC)
8-week MBSC intervention with a focus on increasing self-compassion

Locations

Country Name City State
United States Kootenai Health Coeur d'Alene Idaho
United States Oregon Health & Science University Portland Oregon

Sponsors (5)

Lead Sponsor Collaborator
University of Idaho Kootenai Health, National Institute of General Medical Sciences (NIGMS), Oregon Health and Science University, Oregon State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maternal Stress - Biomarker Change Salivary cortisol - Change from Baseline cortisol to 4 and 8 weeks Baseline to 4 and 8 weeks
Primary Maternal Stress - Psychometric Measure Change Perceived Stress Scale (PSS) - Change from Baseline PSS to 4 and 8 weeks
The Perceived Stress Scale (PSS) is validated and the most widely used instrument to measure perception of stress. The PSS includes 14 questions inquiring about feelings and thoughts during the past month expressed through frequency. The PSS will be used pre-intervention, post-intervention (8 weeks), and at the mid-point of the intervention (4 weeks). The scale for each question ranges from 0-4. The PSS measures how often the responder found life to be unpredictable, uncontrollable, and overloaded. Higher score indicates higher perceived stress. The total score ranges between 0-56.
Baseline to 4 and 8 weeks
Primary Maternal Self-compassion - Biomarker Change Salivary oxytocin - Change from Baseline oxytocin to 4 and 8 weeks Baseline to 4 and 8 weeks
Primary Maternal Self-compassion - Psychometric Measure Change Self-Compassion Scale-Short Form (SCS-SF) - Change from Baseline SCS-SF to 4 and 8 weeks
The Self-Compassion Scale-Short Form (SCS-SF)19 is a shortened and highly correlated (r = 0.97) scale (12 items) from the original 26-item SCS. The SCS-SF measures six key components of self-compassion using a scale that ranges from 1-5: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Self-compassion is associated with psychological well-being and is therefore often measured alongside stress and anxiety. High score indicates higher self-compassion. The total score ranges between 0-60.
Baseline to 4 and 8 weeks
Secondary Human Milk Proteins & Peptides Change Protein and peptide profiles will be measured using proteomic & peptidomic analyses to assess human milk protein and peptide changes from baseline to 4 and 8 weeks as a function of maternal changes in stress/self-compassion. These are measured outcomes. Baseline to 4 and 8 weeks
Secondary Maternal Metabolomic & Transcriptomic Changes Maternal metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to changes in stress/self-compassion. These are measured outcomes. Baseline to 4 and 8 weeks
Secondary Infant Metabolomic & Transcriptomic Changes Infant metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to maternal changes in stress/self-compassion, and human milk protein/peptide profile changes. These are measured outcomes. Baseline to 4 and 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06348316 - Early Half Swaddling and Kangaroo Care Practices on Maternal Sleep Quality and Postpartum Depression in Term Babies N/A
Completed NCT05322161 - Yoga in the NICU for Parents Study N/A
Withdrawn NCT03709004 - Pacifiers and Breastfeeding Among Mothers at Risk for Postpartum Depression N/A
Completed NCT06305325 - Coparenting Intervention to Prevent Postpartum Depression N/A
Not yet recruiting NCT05055674 - The Effects of Motherly on Postpartum Depression N/A
Enrolling by invitation NCT02323152 - PREVENTION OF POSTPARTUM DEPRESSION DEVELOPMENT IN WOMEN WITH VERY HIGH RISK N/A
Not yet recruiting NCT01658098 - Prevalence of Postpartum Depression in Hospital Jose E. Gonzalez N/A
Completed NCT00961402 - The Effect of Exercise on Preventing PostPartum Depression Phase 2
Completed NCT01312883 - Mothers Avoiding Depression Through Empowerment Intervention Trial N/A
Completed NCT00360204 - Improving Health Outcomes for New Mothers and Babies Phase 3
Unknown status NCT00548743 - Translating Research Into Practice for Postpartum Depression N/A
Completed NCT04146025 - Nurtured in Nature N/A
Not yet recruiting NCT06442774 - MamaConecta: Digital Tool for Maternal Mental Health N/A
Recruiting NCT05137925 - Mindful Moms: Mechanisms of Mindfulness-based Cognitive Therapy During Pregnancy and Postpartum N/A
Not yet recruiting NCT05299398 - Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone Phase 1
Completed NCT04925765 - Virtual Reality Biofeedback for Postpartum Anxiety and Depression N/A
Recruiting NCT06053515 - Rosie the Chatbot: Leveraging Automated and Personalized Health Information Communication N/A
Completed NCT04037085 - Ketamine to Improve Recovery After Cesarean Delivery - Part 1 Phase 2
Completed NCT05059600 - A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting Phase 4
Completed NCT06136520 - The Effect of Baby Massage Training Given to Pregnant Women on Maternal Attachment and Postpartum Depression N/A